Cargando…
Prostacyclin: An Inflammatory Paradox
Prostacyclin (PGI(2)) is a member of the prostaglandin family of bioactive lipids. Its best-characterized role is in the cardiovascular system, where it is released by vascular endothelial cells, serving as a potent vasodilator and inhibitor of platelet aggregation. In recent years, prostacyclin (PG...
Autores principales: | Stitham, Jeremiah, Midgett, Charles, Martin, Kathleen A., Hwa, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108482/ https://www.ncbi.nlm.nih.gov/pubmed/21687516 http://dx.doi.org/10.3389/fphar.2011.00024 |
Ejemplares similares
-
Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022) -
Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus
por: Roberts, Maxine J., et al.
Publicado: (2021) -
Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation
por: Mitchell, Jane A., et al.
Publicado: (2021) -
The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
por: Cunningham, Kevin P., et al.
Publicado: (2021) -
Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study
por: Blaser, Lea S, et al.
Publicado: (2021)